VanEck Associates’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $71.5M | Sell |
143,881
-2,235
| -2% | -$991K | 0.04% | 221 |
|
|
2026
Q1 | $65.2M | Sell |
146,116
-3,335
| -2% | -$1.56M | 0.05% | 234 |
|
|
2025
Q4 | $67.8M | Buy |
149,451
+395
| +0.3% | +$170K | 0.06% | 204 |
|
|
2025
Q3 | $58.4M | Buy |
149,056
+8,355
| +6% | +$3.49M | 0.05% | 203 |
|
|
2025
Q2 | $62.6M | Sell |
140,701
-990
| -0.7% | -$456K | 0.07% | 182 |
|
|
2025
Q1 | $68.7M | Sell |
141,691
-17,578
| -11% | -$8.19M | 0.09% | 156 |
|
|
2024
Q4 | $64.1M | Buy |
159,269
+7,841
| +5% | +$3.63M | 0.08% | 159 |
|
|
2024
Q3 | $71.2M | Buy |
151,428
+6,588
| +5% | +$3.16M | 0.09% | 144 |
|
|
2024
Q2 | $67.9M | Sell |
144,840
-7,058
| -5% | -$3.06M | 0.1% | 148 |
|
|
2024
Q1 | $63.5M | Sell |
151,898
-22,329
| -13% | -$9.44M | 0.1% | 144 |
|
|
2023
Q4 | $70.9M | Buy |
174,227
+20,466
| +13% | +$7.56M | 0.13% | 126 |
|
|
2023
Q3 | $53.5M | Sell |
153,761
-10,368
| -6% | -$3.63M | 0.12% | 144 |
|
|
2023
Q2 | $57.8M | Sell |
164,129
-11,535
| -7% | -$3.89M | 0.13% | 139 |
|
|
2023
Q1 | $55.3M | Buy |
175,664
+12,001
| +7% | +$3.6M | 0.13% | 140 |
|
|
2022
Q4 | $47.3M | Sell |
163,663
-11,507
| -7% | -$3.51M | 0.12% | 153 |
|
|
2022
Q3 | $50.7M | Buy |
175,170
+14,239
| +9% | +$4.1M | 0.15% | 139 |
|
|
2022
Q2 | $45.3M | Buy |
160,931
+16,201
| +11% | +$4.34M | 0.12% | 161 |
|
|
2022
Q1 | $37.8M | Sell |
144,730
-14,792
| -9% | -$3.51M | 0.08% | 194 |
|
|
2021
Q4 | $35M | Sell |
159,522
-19,656
| -11% | -$3.82M | 0.08% | 194 |
|
|
2021
Q3 | $32.5M | Buy |
179,178
+37,885
| +27% | +$7.4M | 0.08% | 202 |
|
|
2021
Q2 | $28.5M | Buy |
141,293
+20,403
| +17% | +$4.27M | 0.07% | 217 |
|
|
2021
Q1 | $26M | Buy |
120,890
+8,816
| +8% | +$1.94M | 0.07% | 204 |
|
|
2020
Q4 | $26.5M | Buy |
112,074
+11,937
| +12% | +$2.74M | 0.08% | 186 |
|
|
2020
Q3 | $27.2M | Sell |
100,137
-5,440
| -5% | -$1.5M | 0.09% | 149 |
|
|
2020
Q2 | $30.6M | Buy |
105,577
+30,833
| +41% | +$8.36M | 0.11% | 143 |
|
|
2020
Q1 | $17.8M | Sell |
74,744
-15,326
| -17% | -$3.52M | 0.09% | 153 |
|
|
2019
Q4 | $19.7M | Sell |
90,070
-14,013
| -13% | -$2.84M | 0.08% | 176 |
|
|
2019
Q3 | $17.6M | Sell |
104,083
-6,728
| -6% | -$1.19M | 0.08% | 171 |
|
|
2019
Q2 | $20.3M | Sell |
110,811
-5,617
| -5% | -$982K | 0.1% | 167 |
|
|
2019
Q1 | $21.4M | Buy |
116,428
+1,174
| +1% | +$217K | 0.11% | 155 |
|
|
2018
Q4 | $19.1M | Sell |
115,254
-14,048
| -11% | -$2.43M | 0.1% | 169 |
|
|
2018
Q3 | $24.9M | Sell |
129,302
-10,602
| -8% | -$1.89M | 0.12% | 153 |
|
|
2018
Q2 | $23.8M | Buy |
139,904
+6,799
| +5% | +$1.05M | 0.11% | 155 |
|
|
2018
Q1 | $21.7M | Sell |
133,105
-56,839
| -30% | -$9.28M | 0.11% | 157 |
|
|
2017
Q4 | $28.5M | Sell |
189,944
-17,388
| -8% | -$2.57M | 0.14% | 151 |
|
|
2017
Q3 | $31.5M | Sell |
207,332
-24,813
| -11% | -$3.73M | 0.16% | 133 |
|
|
2017
Q2 | $29.9M | Sell |
232,145
-104,719
| -31% | -$12.6M | 0.16% | 117 |
|
|
2017
Q1 | $36.8M | Sell |
336,864
-3,722
| -1% | -$328K | 0.16% | 107 |
|
|
2016
Q4 | $25.1M | Buy |
340,586
+58,750
| +21% | +$4.78M | 0.13% | 119 |
|
|
2016
Q3 | $24.6M | Buy |
281,836
+25,434
| +10% | +$2.4M | 0.11% | 117 |
|
|
2016
Q2 | $22.1M | Sell |
256,402
-14,403
| -5% | -$1.24M | 0.11% | 107 |
|
|
2016
Q1 | $21.5M | Buy |
270,805
+18,851
| +7% | +$1.71M | 0.15% | 120 |
|
|
2015
Q4 | $31.7M | Buy |
251,954
+803
| +0.3% | +$96.9K | 0.25% | 101 |
|
|
2015
Q3 | $26.2M | Sell |
251,151
-31,626
| -11% | -$4.06M | 0.2% | 111 |
|
|
2015
Q2 | $34.9M | Buy |
282,777
+1,315
| +0.5% | +$166K | 0.21% | 119 |
|
|
2015
Q1 | $33.2M | Buy |
281,462
+34,779
| +14% | +$4.17M | 0.19% | 115 |
|
|
2014
Q4 | $29.3M | Sell |
246,683
-11,988
| -5% | -$1.35M | 0.18% | 116 |
|
|
2014
Q3 | $29.1M | Sell |
258,671
-42,648
| -14% | -$4.06M | 0.15% | 126 |
|
|
2014
Q2 | $28.5M | Sell |
301,319
-59,317
| -16% | -$4.16M | 0.13% | 128 |
|
|
2014
Q1 | $25.5M | Buy |
360,636
+47,283
| +15% | +$3.74M | 0.13% | 128 |
|
|
2013
Q4 | $23.3M | Buy |
313,353
+70,918
| +29% | +$4.94M | 0.12% | 129 |
|
|
2013
Q3 | $18.4M | Buy |
242,435
+62,629
| +35% | +$4.98M | 0.09% | 122 |
|
|
2013
Q2 | $14.4M | Buy |
+179,806
| New | +$13.2M | 0.08% | 122 |
|
Other funds holding VRTX
VanEck Associates's VRTX Position: Q2 2026 in Review
VanEck Associates reduced its Vertex Pharmaceuticals (VRTX) stake by 1.5% in Q2 2026, selling an estimated $991K and leaving 143,881 shares worth $71.5M. The position accounts for 0.04% of the portfolio, ranked #221.
VanEck Associates first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- VanEck Associates held 143,881 shares of Vertex Pharmaceuticals worth $71.5M as of Q2 2026.
- VanEck Associates sold 2,235 Vertex Pharmaceuticals shares in Q2 2026, an estimated $991K.
- Vertex Pharmaceuticals made up 0.04% of VanEck Associates's portfolio in Q2 2026, its #221 holding.
- VanEck Associates first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.